Screening for Free: A Value-Based Insurance Design Natural Experiment
免费筛选:基于价值的保险设计自然实验
基本信息
- 批准号:8733439
- 负责人:
- 金额:$ 55.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-09 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:Advisory CommitteesAge-YearsBreastBudgetsCaringCharacteristicsClinicalColonoscopyColorectalCost SharingDataDiagnostic Neoplasm StagingDrug usageEconomicsEnrollmentEventFeesFutureGoalsGrowthHealth InsuranceHealth Maintenance OrganizationsHospitalizationIncentivesIndividualInpatientsInsuranceInsurance BenefitsLaboratoriesLiteratureMalignant NeoplasmsMammographyMedicalMedicareNational Health PolicyNatural experimentOutcomeOutpatientsPatientsPersonsPharmaceutical PreparationsPhysiciansPolicePoliciesPopulationPopulation StudyPreferred Provider OrganizationsPreventionPreventiveProstateProstate-Specific AntigenRecommendationResearch DesignRoleSampling StudiesScreening for Prostate CancerScreening for cancerServicesStage at DiagnosisStructureSubgroupSystemTestingTimeTumor stageUnited States Centers for Medicare and Medicaid ServicesVariantVisitWomanWorkbasebeneficiarycare systemscolorectal cancer screeningcostcost effectivedesignfinancial incentiveimprovedpaymentscreening
项目摘要
DESCRIPTION (provided by applicant): Aligning health insurance benefits with clinical goals, aka value-based insurance design (VBID), holds much promise for reducing financial barriers to recommended care, improving quality, and modulating spending growth. While studies have found that patient cost-sharing can reduce the use of necessary care and increase spending for downstream care such as hospitalizations, there have been few rigorous VBID studies, especially of the effects on overall clinical or spending outcomes. The Patient Protection and Affordable Care Act (ACA) requires that all Medicare beneficiaries have free access to preventive services starting in 2011, thus creating a VBID natural experiment. This elimination of cost-sharing has the potential to mitigate underuse of cancer screening tests recommended by the US Preventive Services Task Force (USPSF). Using information from large Medicare Advantage plans, this project will examine the clinical and economic effects of this ACA- mandated Medicare policy change. Our 2007-2014 data contain detailed, comprehensive information on insurance benefits, individual characteristics, testing, clinical events, and medical spending. The study sample includes beneficiaries with a range of pre-policy cost-sharing amounts with the staggered elimination of cost- sharing (free screening) over time. For example, 46% of the study population had free colorectal cancer screening in 2007, 74% in 2010, and 100% in 2011; all benefit changes occur on January 1st of the year. The three aims examine the cost-sharing changes' direct and overall effects: Aim 1) screening test rates; Aim 2) clinical event rates; and Aim 3) total medical spending. We will evaluate the outcomes in all subjects and illustrative subgroups, e.g., subjects for whom screening may be of high or low value as per the USPSTF recommendations. Our primary analyses will focus on within-person changes (fixed effects estimation), and will adjust for a rich set of demographic, clinical, physician, and system characteristics. We also will compare subjects with cost-sharing versus those without cost-sharing, using as concurrent controls subjects who consistently have free screening throughout the study period. With several million person-years of data, we will have adequate power to detect even small changes in our outcomes. This study provides an opportunity to evaluate the largest VBID natural experiment to date, to examine the early effects of a major ACA provision on access to preventive care, and to inform future Medicare policy decisions.
描述(由申请人提供):将健康保险福利与临床目标相结合,即基于价值的保险设计(VBID),对于减少推荐护理的财务障碍,提高质量和调节支出增长有很大的希望。虽然研究发现,患者费用分摊可以减少必要护理的使用,并增加下游护理(如住院)的支出,但很少有严格的VBID研究,特别是对整体临床或支出结果的影响。《病人保护和平价医疗法案》(ACA)要求所有医疗保险受益人从2011年开始免费获得预防服务,从而创造了一个VBID自然实验。这种费用分摊的消除有可能减轻美国预防服务工作组(USPSF)推荐的癌症筛查测试的使用不足。利用来自大型医疗保险优势计划的信息,该项目将研究ACA授权的医疗保险政策变化的临床和经济影响。我们2007-2014年的数据包含有关保险福利,个人特征,测试,临床事件和医疗支出的详细,全面的信息。研究样本包括受益人,他们在投保前有一系列费用分摊数额,随着时间的推移,费用分摊(免费筛查)逐步取消。例如,2007年有46%的研究人群接受了免费的结直肠癌筛查,2010年为74%,2011年为100%;所有的福利变化都发生在每年的1月1日。这三个目标检查了费用分摊变化的直接和总体影响:目标1)筛查率;目标2)临床事件率;目标3)总医疗支出。我们将评估所有受试者和说明性亚组的结果,例如,根据USPSTF的建议,筛选可能具有高或低价值的受试者。我们的主要分析将集中在人内变化(固定效应估计),并将调整丰富的人口统计学,临床,医生和系统特征。我们还将比较分担费用的受试者与不分担费用的受试者,并使用在整个研究期间始终接受免费筛查的受试者作为并行对照。有了数百万人年的数据,我们将有足够的能力检测到我们结果中甚至很小的变化。这项研究提供了一个机会,以评估迄今为止最大的VBID自然实验,以检查一个主要的ACA条款对获得预防保健的早期影响,并告知未来的医疗保险政策决定。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN HSU其他文献
JOHN HSU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN HSU', 18)}}的其他基金
Impact of Medicare Polices on Beneficiaries with ADRD
医疗保险政策对 ADRD 受益人的影响
- 批准号:
10728582 - 财政年份:2023
- 资助金额:
$ 55.66万 - 项目类别:
Impact of the COVID-19 Pandemic on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias
COVID-19 大流行对阿尔茨海默病和阿尔茨海默病相关痴呆症患者的影响
- 批准号:
10683255 - 财政年份:2021
- 资助金额:
$ 55.66万 - 项目类别:
Impact of the COVID-19 Pandemic on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias
COVID-19 大流行对阿尔茨海默病和阿尔茨海默病相关痴呆症患者的影响
- 批准号:
10423845 - 财政年份:2021
- 资助金额:
$ 55.66万 - 项目类别:
Alzheimer's Disease and Related Dementia Care within the Medicare Program
医疗保险计划内的阿尔茨海默病和相关痴呆症护理
- 批准号:
10413262 - 财政年份:2018
- 资助金额:
$ 55.66万 - 项目类别:
Alzheimer's Disease and Related Dementia Care within the Medicare Program
医疗保险计划内的阿尔茨海默病和相关痴呆症护理
- 批准号:
10221576 - 财政年份:2018
- 资助金额:
$ 55.66万 - 项目类别:
COVID-19 and Acute Medical Care: Impact on Dementia Patients
COVID-19 和紧急医疗护理:对痴呆症患者的影响
- 批准号:
10168228 - 财政年份:2018
- 资助金额:
$ 55.66万 - 项目类别:
Alzheimer's Disease and Related Dementia Care within the Medicare Program
医疗保险计划内的阿尔茨海默病和相关痴呆症护理
- 批准号:
9789181 - 财政年份:2018
- 资助金额:
$ 55.66万 - 项目类别:
To Screen or Not To Screen: Prevention Decisions and Competing Risks
筛查或不筛查:预防决策和竞争风险
- 批准号:
8727778 - 财政年份:2014
- 资助金额:
$ 55.66万 - 项目类别:
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
新英格兰提高 SMI 患者生存率的固定剂量干预试验
- 批准号:
8919458 - 财政年份:2014
- 资助金额:
$ 55.66万 - 项目类别:
Screening for Free: A Value-Based Insurance Design Natural Experiment
免费筛选:基于价值的保险设计自然实验
- 批准号:
8913062 - 财政年份:2012
- 资助金额:
$ 55.66万 - 项目类别:
相似海外基金
PREDICTING CARIES RISK IN UNDERSERVED CHILDREN, FROM TODDLERS TO THE SCHOOL-AGE YEARS, IN PRIMARY HEALTHCARE SETTINGS
预测初级医疗保健机构中从幼儿到学龄儿童的龋齿风险
- 批准号:
10361268 - 财政年份:2021
- 资助金额:
$ 55.66万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9751077 - 财政年份:2011
- 资助金额:
$ 55.66万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10457019 - 财政年份:2011
- 资助金额:
$ 55.66万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
9976990 - 财政年份:2011
- 资助金额:
$ 55.66万 - 项目类别:
Predicting Caries Risk in Underserved Children, from Toddlers to the School-Age Years, in Primary Healthcare Settings
预测初级医疗机构中服务不足的儿童(从幼儿到学龄儿童)的龋齿风险
- 批准号:
10213006 - 财政年份:2011
- 资助金额:
$ 55.66万 - 项目类别:














{{item.name}}会员




